Peptides and combinations of peptides for use in immunotherapy against an infection by sars-cov-2 (covid-19)
AssigneeEberhard Karls Universität Tübingen Medizinische Fakultät
InventorsJuliane Walz, Annika Nelde, Hans-Georg Rammensee, Tatjana Bilich
Life of this patent
Estimating the term…
Abstract
SARS-CoV2-associated T-cell peptide epitopes as active pharmaceutical ingredients of vaccine compositions to stimulate anti-SARS-CoV2 immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides of SARS-CoV2-associated T-cell peptide epitopes bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Claims23
A peptide comprising an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 1 to SEQ ID NO:
- 110, and variants thereof which are at least 88% homologous to SEQ ID NO:
- 1 to SEQ ID NO:
- 110, and wherein said variants bind to molecule(s) of the major histocompatibility complex (MHC) or induces T cells cross-reacting with said variants;
- and a pharmaceutical acceptable salt thereof, wherein said peptide is not a full-length polypeptide.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.